Oragenics, Inc. (OGEN:NYSEMKT) closed at $0.343 on November 10, 2026, down 3.30% on the day. The stock trades 71.9% below its 52-week high of $1.22 and 0.9% above its 52-week low of $0.340. Over the past year, it lost 68.3%. Oragenics, Inc. is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since November 10, 2025, OGEN closed higher on 89 days (35%). Its best day was April 13, 2026 (+13.33%) and its worst was February 5, 2026 (-13.33%). The stock moved 10% or more in a single session 10 times. It opened at least 5% above the previous day's high 6 times.
Oragenics, Inc. focuses on developing antibiotics against infectious diseases and treatments for oral mucositis. It is developing OG716, an antibiotic product candidate, which is in nonclinical testing for healthcare-associated infections, as well as other homolog antibiotic product candidates. The company is also developing AG013, which is in initiation of Phase II clinical trial for the treatment of oral mucositis in cancer patients. Its products also comprise LPT3-04, a naturally occurring dietary substance for weight loss; and SMaRT Replacement Therapy, a topical treatment applied to the teeth to protect against tooth decay. Oragenics, Inc. has license agreement with Intrexon Corporation to use its technology to develop lantibiotics; and Intrexon Corporation and its wholly owned subsidiary, Actobiotics NV to use their intellectual property to develop AG013. It also has license agreement with LPThera LLC to develop LPT3-04 weight-loss product candidate; and Texas A&M University System for access to new homologs of the lantibiotic Mutacin 1140 (MU1140) and other lantibiotics, as well as holds licenses from the University of Florida Research Foundation, Inc. for MU1140 product can...
Find more stocks like OGEN with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.